Navigation Links
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Date:12/1/2008

its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Merck will complete the Phase I clinical trial of its cancer vaccine; whether genes encoding hTERT will trigger immune responses against cancer cells; whether the cancer vaccine will be shown to be safe and effective in clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

    Contact:  Alan R. Engbring
    (858) 646-1127

Website: www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy ... clinics opened in Memphis and ... added in Springfield on September 24 and ... to open October 22.  MinuteClinic is the largest and fastest growing ... . The Memphis -area clinics ...
(Date:9/19/2014)... DIEGO , Sept. 19, 2014  Lpath, ... leader in bioactive lipid-targeted therapeutics, announced today that ... 3,605,042 registered shares of common stock and 3,605,042 ... combined purchase price for one registered share of ... one unregistered share of common stock will be ...
(Date:9/19/2014)... 2014 Intarcia Therapeutics, Inc. today ... its lead candidate ITCA 650 (continuous subcutaneous delivery of ... HbA1c levels at the 50 th Annual Meeting ... (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high ... in patients with poorly controlled type 2 diabetes. The ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... 2011 Volcano Corporation (NASDAQ: VOLC ), ... and therapy guidance tools designed to enhance the treatment ... it will be participating in two upcoming investor conferences. ... participate in the Stifel Nicolaus Healthcare Conference 2011. The ...
... Sept. 1, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical ... Botanic" or the "Company"), a developer, manufacturer and ... medicines ("TCM") in China, today announced that the ... a key research laboratory ("the laboratory") in cooperation ...
Cached Medicine Technology:Volcano Corporation Announces Presentations at Upcoming Investor Conferences 2China Botanic Pharmaceutical Enters into Research Cooperation with Key Laboratory of Forest Plant Ecology 2China Botanic Pharmaceutical Enters into Research Cooperation with Key Laboratory of Forest Plant Ecology 3
(Date:9/20/2014)... September 21, 2014 6 Minutes to ... fitness expert Craig Ballantyne that is showing men and women ... blast away stubborn body fat using simple 6-minute exercises and ... Michaels, prompting an investigative review. , “When it comes ... in vs. calories out for all people,” reports Michaels. “Metabolism ...
(Date:9/20/2014)... Melbourne, Australia (PRWEB) September 21, 2014 ... levels are contributing to greater waste treatment volumes. ... are increasingly diverting waste from landfill. According to ... decade, governments have implemented strategies aimed at reducing ... amount of waste recycled and recovered.” Still, a ...
(Date:9/20/2014)... September 20, 2014 As testosterone ... in federal court, Bernstein Liebhard LLP notes that ... (FDA) have voted overwhelmingly to recommend that prescription ... be subjected to further study in order to ... published on September 18th by Bloomberg.com, the panel ...
(Date:9/20/2014)... Sept. 20, 2014 (HealthDay News) -- As flu season ... infection is to get a flu shot and a ... A primary care doctor can vaccinate people against the ... patients may have. Retail stores may provide flu shots ... advice, said Dr. Jorge Parada, medical director of infection ...
(Date:9/20/2014)... York (PRWEB) September 20, 2014 ... ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continue ... another insurer has announced plans to end coverage ... on its website last month, Harrisburg, Pennsylvania-based Capital ... November 1, 2014. The insurer said its decision ...
Breaking Medicine News(10 mins):Health News:6 Minutes to Skinny: Review Exposes Craig Ballantyne’s Method to Jump Starting the Metabolism and Blasting Away Body Fat in Just 6 Minutes Per Day 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3
... of MRSA that causes bloodstream infections is five times more ... resistance to the potent antibiotic drug vancomycin used to treat ... study found that 50 percent of the patients infected with ... of patients infected with other MRSA strains. The ...
... During Last Year,s ,One Million Tests, World AIDS Day ... Testing Goal by Testing 35,034 , PHNOM PENH, Cambodia, ... to test several million people for HIV in observance of ... 2009 campaign, AHF/Cambodia CARES will launch its inaugural testing effort ...
... be reserved for the most seriously ill, experts say , ... to fight anemia appears to double the risk of stroke ... their quality of life, a new study finds. , ... agent (ESA), is often prescribed for diabetic patients with chronic ...
... Oct. 30 Amgen (Nasdaq: AMGN ) today ... to Reduce Cardiovascular Events with Aranesp® Therapy), a large, ... with chronic kidney disease (CKD) not on dialysis, moderate ... in the New England Journal of Medicine ...
... Beach, CA; December 8, 2009 , NEEDHAM, Mass., Oct. ... a special event, Terminology Services Information Day, will be co-located ... on December 8, 2009. For more information and to register ... . , (Logo: http://www.newscom.com/cgi-bin/prnh/20090629/DC39325LOGO ...
... Oct. 30 A hospital group based in McAllen, ... to settle claims that it violated the False Claims Act, ... 2006, by paying illegal compensation to doctors in order to ... the Justice Department announced today. McAllen Hospitals L.P., d/b/a/ South ...
Cached Medicine News:Health News:Henry Ford Hospital study: A MRSA strain linked to high death rates 2Health News:Cambodia: World AIDS Day HIV Campaign, 'Testing Millions,' to Again Launch During Cambodia's National Water Festival 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 2Health News:Anemia Drug May Raise Stroke Risk in Kidney Patients 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 2Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 4Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 5Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 6Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 7Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 8Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 9Health News:OMG Announces Special Event: Terminology Services Information Day 2Health News:OMG Announces Special Event: Terminology Services Information Day 3Health News:Texas Hospital Group Pays U.S. $27.5 Million to Settle False Claims Act Allegations 2Health News:Texas Hospital Group Pays U.S. $27.5 Million to Settle False Claims Act Allegations 3
... Inserted into the punctal opening to ... collagen plugs provide temporary relief of ... precisely measured premium collagen, Used as ... occlusion, Available in standard and short ...
... head combined with a softer more flexible ... design simplifies insertion and the large anchor ... dislocation less likely. The inserter provides ... SOFT PLUG Silicone Plugs are removable. Available ...
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
Attain CS Leads. Navigate minimally angled veins with no tortuosity....
Medicine Products: